NASDAQ:VCYT Veracyte (VCYT) Stock Price, News & Analysis → They said crypto was dead. It went up 100X. (From InvestorPlace) (Ad) Free VCYT Stock Alerts $21.58 +0.48 (+2.27%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$20.98▼$21.6550-Day Range$21.10▼$28.2952-Week Range$19.52▼$30.52Volume962,568 shsAverage Volume641,967 shsMarket Capitalization$1.58 billionP/E RatioN/ADividend YieldN/APrice Target$30.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Veracyte alerts: Email Address Veracyte MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.60 Rating ScoreUpside/Downside39.0% Upside$30.00 Price TargetShort InterestBearish3.73% of Shares Sold ShortDividend StrengthN/ASustainability-1.02Upright™ Environmental ScoreNews Sentiment1.36Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.29) to ($0.04) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.65 out of 5 starsMedical Sector281st out of 947 stocksMedical Laboratories Industry10th out of 19 stocks 3.3 Analyst's Opinion Consensus RatingVeracyte has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 4 buy ratings, no hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $30.00, Veracyte has a forecasted upside of 39.0% from its current price of $21.58.Amount of Analyst CoverageVeracyte has only been the subject of 3 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted3.73% of the outstanding shares of Veracyte have been sold short.Short Interest Ratio / Days to CoverVeracyte has a short interest ratio ("days to cover") of 4.4.Change versus previous monthShort interest in Veracyte has recently increased by 11.93%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldVeracyte does not currently pay a dividend.Dividend GrowthVeracyte does not have a long track record of dividend growth. Previous Next 4.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreVeracyte has received a 63.11% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Diagnostic test kits", "Management consulting for the pharmaceutical industry", and "DNA sequencers" products. See details.Environmental SustainabilityThe Environmental Impact score for Veracyte is -1.02. Previous Next 3.0 News and Social Media Coverage News SentimentVeracyte has a news sentiment score of 1.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.64 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Veracyte this week, compared to 3 articles on an average week.MarketBeat Follows4 people have added Veracyte to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Veracyte insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.60% of the stock of Veracyte is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Veracyte are expected to grow in the coming year, from ($0.29) to ($0.04) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Veracyte is -20.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Veracyte is -20.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVeracyte has a P/B Ratio of 1.51. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsThe only AI company you should be looking atThis is the ONLY AI company you should be watching right now. No. It's not Nvidia, Intel, or Microsoft... It's a tiny biotech using proprietary AI to assist in new drug discovery at a rate 100,000 times faster than a human. This new drug discovery technique will change the market. And that's why they received a $50 million investment from an AI powerhouse.Get the stock ticker here >>> About Veracyte Stock (NASDAQ:VCYT)Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. It is also developing Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.Read More VCYT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VCYT Stock News HeadlinesMarch 16, 2024 | finance.yahoo.comVCYT Apr 2024 30.000 callFebruary 27, 2024 | businesswire.comVeracyte's Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN GuidelinesMarch 19, 2024 | Banyan Hill Publishing (Ad)AI Cracks Open Largest Untapped Energy Reserve on EarthThis orb represents the largest untapped energy source in the world… And although this energy resource is unknown by 99% of the public… It makes gas, coal, oil, wind, hydropower, solar, fusion… February 26, 2024 | investorplace.com7 Under-the-Radar Biotech Stocks Gearing Up for LiftoffFebruary 26, 2024 | markets.businessinsider.comVeracyte’s Strategic Growth and Market Positioning Inspire Positive Analyst OutlookFebruary 24, 2024 | finance.yahoo.comVeracyte Full Year 2023 Earnings: Revenues Beat Expectations, EPS LagsFebruary 23, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Veracyte (VCYT), Irhythm Technologies (IRTC)February 23, 2024 | finance.yahoo.comVeracyte, Inc. (NASDAQ:VCYT) Q4 2023 Earnings Call TranscriptMarch 19, 2024 | Banyan Hill Publishing (Ad)AI Cracks Open Largest Untapped Energy Reserve on EarthThis orb represents the largest untapped energy source in the world… And although this energy resource is unknown by 99% of the public… It makes gas, coal, oil, wind, hydropower, solar, fusion… February 22, 2024 | benzinga.comRecap: Veracyte Q4 EarningsFebruary 22, 2024 | finance.yahoo.comVeracyte Inc (VCYT) Reports 22% Revenue Growth in 2023, Maintains Positive Cash Flow OutlookFebruary 22, 2024 | seekingalpha.comVeracyte, Inc. 2023 Q4 - Results - Earnings Call PresentationFebruary 22, 2024 | businesswire.comVeracyte Announces Fourth Quarter and Full-Year 2023 Financial ResultsFebruary 21, 2024 | finance.yahoo.comVeracyte to Participate in the Raymond James 45th Annual Institutional Investors ConferenceFebruary 21, 2024 | businesswire.comVeracyte to Participate in the Raymond James 45th Annual Institutional Investors ConferenceFebruary 19, 2024 | finance.yahoo.comVCYT Mar 2024 35.000 putFebruary 17, 2024 | finance.yahoo.comVCYT Mar 2024 20.000 putFebruary 8, 2024 | finance.yahoo.comVeracyte to Release Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024February 7, 2024 | msn.comVeracyte Finalizes C2i Genomics Acquisition DealFebruary 6, 2024 | stockhouse.comVeracyte Completes Acquisition of C2i GenomicsJanuary 23, 2024 | finance.yahoo.com3 Medical Instruments Stocks to Buy as Industry Trends ImproveJanuary 11, 2024 | markets.businessinsider.comBuy Rating Affirmed for Veracyte Amid Strong Financials and Strategic MRD Market AcquisitionJanuary 9, 2024 | markets.businessinsider.comSolid Growth and Strategic Acquisition Bolster Buy Rating for VeracyteJanuary 8, 2024 | markets.businessinsider.comVeracyte Expects Higher Q4, FY23 Revenue Better Than View; To Acquire C2i GenomicsJanuary 8, 2024 | finance.yahoo.comVeracyte Announces Preliminary Full-Year 2023 Results, Acquisition of C2i Genomics to Add Minimal Residual Disease Capabilities to Its Novel Diagnostics PlatformDecember 20, 2023 | benzinga.comVeracyte Stock (NASDAQ:VCYT) Dividends: History, Yield and DatesDecember 19, 2023 | ca.finance.yahoo.comVeracyte, Inc. (VCYT) Stock Price, News, Quote & History - Yahoo FinanceSee More Headlines Receive VCYT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Veracyte and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/22/2024Today3/19/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryN/A Current SymbolNASDAQ:VCYT CUSIPN/A CIK1384101 Webwww.veracyte.com Phone(650) 243-6300Fax650-243-6301Employees815Year Founded2006Price Target and Rating Average Stock Price Target$30.00 High Stock Price Target$34.00 Low Stock Price Target$21.00 Potential Upside/Downside+39.0%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-74,400,000.00 Net Margins-20.61% Pretax Margin-21.22% Return on Equity-2.02% Return on Assets-1.89% Debt Debt-to-Equity RatioN/A Current Ratio4.66 Quick Ratio4.40 Sales & Book Value Annual Sales$361.05 million Price / Sales4.36 Cash Flow$0.09 per share Price / Cash Flow229.06 Book Value$14.30 per share Price / Book1.51Miscellaneous Outstanding Shares73,000,000Free Float71,102,000Market Cap$1.58 billion OptionableOptionable Beta1.64 Social Links 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Marc A. Stapley (Age 54)CEO & Director Comp: $1.25MMs. Rebecca Chambers (Age 46)Executive VP & CFO Comp: $772.41kMs. Annie McGuire (Age 43)Executive VP, General Counsel & Chief People Officer Comp: $633.65kMr. Jonathan Wygant (Age 53)VP & Chief Accounting Officer Mr. Steven FrenchSenior VP & Chief Information OfficerDr. Phillip G. Febbo M.D. (Age 58)Chief Scientific & Medical Officer Ms. Karen PossematoSenior Vice President of Corporate Marketing, Communications & Commercial OperationsMr. Robert Brainin (Age 53)Executive VP & Chief Business Officer Dr. John Leite Ph.D.Chief Commercial Officer for CLIA BusinessMs. Corinne DananSenior VP and GM of Biopharma & IVD ServicesMore ExecutivesKey CompetitorsViridian TherapeuticsNASDAQ:VRDNGuardant HealthNASDAQ:GHFulgent GeneticsNASDAQ:FLGTCareDxNASDAQ:CDNACastle BiosciencesNASDAQ:CSTLView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 52,699 shares on 3/11/2024Ownership: 9.751%Wellington Management Group LLPBought 571 shares on 3/5/2024Ownership: 9.416%Fisher Asset Management LLCSold 130,268 shares on 3/5/2024Ownership: 1.166%Goldman Sachs Group Inc.Sold 90,216 shares on 3/1/2024Ownership: 1.665%Eventide Asset Management LLCSold 168,000 shares on 2/20/2024Ownership: 0.772%View All Insider TransactionsView All Institutional Transactions VCYT Stock Analysis - Frequently Asked Questions Should I buy or sell Veracyte stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Veracyte in the last year. There are currently 1 sell rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" VCYT shares. View VCYT analyst ratings or view top-rated stocks. What is Veracyte's stock price target for 2024? 5 Wall Street research analysts have issued 12-month target prices for Veracyte's shares. Their VCYT share price targets range from $21.00 to $34.00. On average, they predict the company's share price to reach $30.00 in the next twelve months. This suggests a possible upside of 39.0% from the stock's current price. View analysts price targets for VCYT or view top-rated stocks among Wall Street analysts. How have VCYT shares performed in 2024? Veracyte's stock was trading at $27.51 on January 1st, 2024. Since then, VCYT stock has decreased by 21.6% and is now trading at $21.58. View the best growth stocks for 2024 here. When is Veracyte's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our VCYT earnings forecast. How were Veracyte's earnings last quarter? Veracyte, Inc. (NASDAQ:VCYT) released its earnings results on Thursday, February, 22nd. The biotechnology company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.03. The biotechnology company had revenue of $98.20 million for the quarter, compared to analyst estimates of $95.49 million. Veracyte had a negative trailing twelve-month return on equity of 2.02% and a negative net margin of 20.61%. What ETFs hold Veracyte's stock? ETFs with the largest weight of Veracyte (NASDAQ:VCYT) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM), Global X Telemedicine & Digital Health ETF (EDOC), Invesco Biotechnology & Genome ETF (PBE), ARK Genomic Revolution ETF (ARKG), ROBO Global Healthcare Technology and Innovation ETF (HTEC), ARK Innovation ETF (ARKK), WisdomTree BioRevolution Fund (WDNA) and ARK Next Generation Internation ETF (ARKW). What guidance has Veracyte issued on next quarter's earnings? Veracyte updated its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $394.0 million-$402.0 million, compared to the consensus revenue estimate of $393.3 million. What other stocks do shareholders of Veracyte own? Based on aggregate information from My MarketBeat watchlists, some companies that other Veracyte investors own include Hawkins (HWKN), Invitae (NVTA), AbbVie (ABBV), Xtrackers California Municipal Bond ETF (CA), CRISPR Therapeutics (CRSP), Advanced Micro Devices (AMD), Editas Medicine (EDIT), NVIDIA (NVDA), Exelixis (EXEL) and NeoGenomics (NEO). Who are Veracyte's major shareholders? Veracyte's stock is owned by many different institutional and retail investors. Top institutional shareholders include ARK Investment Management LLC (10.48%), Vanguard Group Inc. (9.75%), Vanguard Group Inc. (9.75%), Wellington Management Group LLP (9.42%), Dimensional Fund Advisors LP (4.62%) and Artisan Partners Limited Partnership (4.41%). Insiders that own company stock include Bonnie H Anderson, Evan/ Fa Jones, Giulia C Kennedy, Giulia C Kennedy, Jens Holstein, John L Bishop, Karin Eastham, Marc Stapley and Muna Bhanji. View institutional ownership trends. How do I buy shares of Veracyte? Shares of VCYT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does Veracyte have any subsidiaries? The following companies are subsidiares of Veracyte: Allegro Diagnostics, Decipher Biosciences Inc., Decipher Corp., Delight Merger Sub II LLC, HalioDx Inc., Veracyte Global B.V., Veracyte International Corp., and Veracyte SAS.Read More This page (NASDAQ:VCYT) was last updated on 3/19/2024 by MarketBeat.com Staff From Our Partners8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressCentral Bank Gold Heist In ProgressColonial MetalsLike Tiny Crypto Retirement FundsCrypto 101 MediaThe AI Bottleneck No One is Talking AboutThe Bull ReportMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThe world’s greatest investmentPorter & CompanyBuy this small stock before coming AI Tidal WaveChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Veracyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.